BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 21,000 Shares

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 21,000 shares of the company’s stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $96.81, for a total transaction of $2,033,010.00. Following the completion of the transaction, the chief executive officer owned 87,209 shares in the company, valued at approximately $8,442,703.29. The trade was a 19.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Monday, October 5th, Ugur Sahin sold 72,000 shares of BioNTech stock. The shares were sold at an average price of $97.23, for a total transaction of $7,000,560.00.
• On Thursday, October 1st, Ugur Sahin sold 17,000 shares of BioNTech stock. The shares were sold at an average price of $97.46, for a total transaction of $1,656,820.00.
• On Wednesday, September 30th, Ugur Sahin sold 32,000 shares of BioNTech stock. The stock was sold at an average price of $98.12, for a total transaction of $3,139,840.00.
• On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.47, for a total transaction of $3,347,980.00.
• On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The shares were sold at an average price of $98.69, for a total transaction of $2,664,630.00.
• On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The shares were sold at an average price of $98.99, for a total transaction of $3,860,610.00.
• On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $99.40, for a total transaction of $2,982,000.00.
• On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The stock was sold at an average price of $100.72, for a total transaction of $4,633,120.00.
• On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The shares were sold at an average price of $97.81, for a total value of $3,227,730.00.
• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $96.22, for a total value of $2,886,600.00.

BioNTech Stock Down 1.9%

BNTX traded down $1.81 during trading on Tuesday, hitting $95.83. 899,354 shares of the company’s stock traded hands, compared to its average volume of 1,088,477. The stock has a market capitalization of $24.23 billion, a price-to-earnings ratio of -12.24 and a beta of 1.25. The company’s 50 day simple moving average is $98.94 and its two-hundred day simple moving average is $95.06. BioNTech SE Sponsored ADR has a 12-month low of $79.52 and a 12-month high of $124.00. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The business had revenue of $122.31 million during the quarter, compared to analysts’ expectations of $180.18 million. During the same quarter in the prior year, the firm earned ($1.60) EPS. The firm’s revenue for the quarter was down 59.5% compared to the same quarter last year. Analysts predict that BioNTech SE Sponsored ADR will post -6.37 earnings per share for the current fiscal year.

Institutional Trading of BioNTech

Large investors have recently added to or reduced their stakes in the business. Integrated Wealth Concepts LLC bought a new position in BioNTech in the second quarter worth approximately $39,000. Caitong International Asset Management Co. Ltd grew its position in shares of BioNTech by 1,012.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company’s stock valued at $53,000 after acquiring an additional 506 shares during the period. Vestcor Inc bought a new stake in shares of BioNTech during the 4th quarter valued at $153,000. Rockefeller Capital Management L.P. increased its stake in shares of BioNTech by 328.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company’s stock worth $177,000 after purchasing an additional 1,423 shares in the last quarter. Finally, Quantum Portfolio Management LLC purchased a new stake in shares of BioNTech in the 1st quarter worth $203,000. 15.52% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on BNTX shares. Canaccord Genuity Group decreased their price objective on shares of BioNTech from $142.00 to $136.00 and set a “buy” rating for the company in a report on Monday, August 31st. Morgan Stanley cut their target price on shares of BioNTech from $126.00 to $119.00 and set an “overweight” rating for the company in a research report on Wednesday, July 8th. Wall Street Zen lowered shares of BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Berenberg Bank set a $140.00 price target on BioNTech in a report on Wednesday, September 16th. Finally, Citigroup lowered their price target on BioNTech from $130.00 to $125.00 and set a “buy” rating on the stock in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $126.00.

About BioNTech

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.